@article{a5828f7e874a41e484a734afcc20044a,
title = "Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review",
abstract = "Bipolar disorder (BD) might be associated with higher infection rates of coronavirus disease (COVID-19) which in turn could result in worsening the clinical course and outcome. This may be due to a high prevalence of somatic comorbidities and an increased risk of delays in and poorer treatment of somatic disease in patients with severe mental illness in general. Vaccination is the most important public health intervention to tackle the ongoing pandemic. We undertook a systematic review regarding the data on vaccinations in individuals with BD. Proportion of prevalence rates, efficacy and specific side effects of vaccinations and in individuals with BD were searched. Results show that only five studies have investigated vaccinations in individuals with BD, which substantially limits the interpretation of overall findings. Studies on antibody production after vaccinations in BD are very limited and results are inconsistent. Also, the evidence-based science on side effects of vaccinations in individuals with BD so far is poor.",
keywords = "Bipolar disorder, COVID-19, Infectious diseases, Systematic review, Vaccination",
author = "Reininghaus, {Eva Z.} and Mirko Manchia and Nina Dalkner and Nina Bonkat and Alessio Squassina and Isabel Hodl and Eduard Vieta and Andreas Reif and Tomas Hajek and Mikael Land{\'e}n and Correll, {Christoph U.} and Jan Scott and Bruno Etain and Marcella Rietschel and Veerle Bergink and Monica Martinez-Cengotitabengoa and Kessing, {Lars Vedel} and Andrea Fagiolini and Michael Bauer and Guy Goodwin and Ana Gonzalez-Pinto and Kupka, {Ralph W.} and Schulze, {Thomas G.} and Lagerberg, {Trine V.} and Ay{\c s}eg{\"u}l Yildiz and Chantal Henry and Gunnar Morken and Phillip Ritter and Nieslen, {Ren{\'e} Ernst} and Licht, {Rasmus W.} and Andreas Bechdolf and Andreassen, {Ole A.} and Fellendorf, {Frederike Tabea}",
note = "Funding Information: AF is /has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Boheringer Ingelheim, Daiichi Sankyo, Doc Generici, Glaxo Smith Kline, Italfarmaco, Lundbeck, Janssen, Mylan, Neuraxpharm, Otsuka, Pfizer, Recordati, Sanofi Aventis, Sunovion, Vifor. Funding Information: MB has received institutional grants from Deutsche Forschungsgemeinschaft (DFG), Bundesministerium f{\"u}r Bildung und Forschung (BMBF), and European Commission. He served in advisory boards for GH Research, Janssen-Cilag, neuraxpharm, Novartis, Sandoz, Shire International, Sumitomo Dainippon, Sunovion, and Takeda, and received speaker honoraria for Aristo, Hexal, Janssen Pharmaceutica NV, Janssen-Cilag, and Sunovion, outside the submitted work. Funding Information: CC has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. Publisher Copyright: {\textcopyright} 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2022",
month = jan,
doi = "https://doi.org/10.1016/j.euroneuro.2021.09.001",
language = "English",
volume = "54",
pages = "90--99",
journal = "European Neuropsychopharmacology",
issn = "1873-7862",
publisher = "Elsevier",
}